TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00734656
Drug: placebo medication + placebo alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
Study: NCT01471444
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
Study: NCT01677182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets for sublingual administration
Study: NCT02632370
Drug: Gliolan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
Study: NCT01400906
Drug: lactose powder
Normalized name: Lactose Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose powder in dry powder device : placebo comparator
Study: NCT01041274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth daily for 12 months.
Study: NCT00985660
Drug: Sular® Extended Release Tablets, 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 30 mg Tablet under fasting conditions
Study: NCT02155088
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation beginning at 250 mg/day
Study: NCT04032197
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
Study: NCT01874626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream
Study: NCT01874626
Drug: SST-0225 Topical Ibuprofen Cream
Normalized name: ibuprofen Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: SST-0225 Topical Ibuprofen Cream
Study: NCT00612651
Drug: Temodar and SCH 66336
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated \& escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle \& escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning \& evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 \& 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
Study: NCT02429102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02146209
Drug: Flagyl 125 mg/5 ml oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 500 mg (20 ml suspension)
Study: NCT00790556
Drug: MK8245
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
Study: NCT00790556
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
Study: NCT01481402
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liothyronine 40 microgram per day
Study: NCT01481402
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
Study: NCT00348335
Drug: Ocular lubricant
Normalized name: ocular lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00165217
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02455453
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00368459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical appearing placebo
Study: NCT01062009
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 200 mcg/ml in Normal Saline
Study: NCT03610334
Drug: IFB-088 (2.5-60.0mg) oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
Study: NCT03610334
Drug: Placebo (2.5-60.mg) oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
Study: NCT03610334
Drug: IFB-088 (15.0-50.0mg) oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
Study: NCT03610334
Drug: Placebo oral (15.0-50.0mg) capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
Study: NCT02020889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as 0.9% sodium chloride
Study: NCT00809094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00397189
Drug: placebo circadin
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo circadin tablets
Study: NCT00893074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo dronabinol administered 3x/day for 5 days
Study: NCT04470479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00287729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
Study: NCT01515202
Drug: Placebo matching with BMS-823778
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, Once daily, 14 days
Study: NCT00966641
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single orally administered dose of 500 mg naproxen
Study: NCT00966641
Drug: PL 3100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single orally administered dose of PL 3100 (500 mg naproxen)
Study: NCT00170950
Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
Study: NCT00170950
Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
Study: NCT02334345
Drug: Evoskin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
Study: NCT02334345
Drug: Trixiera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
Study: NCT00170950
Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
Study: NCT01939223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
Study: NCT01860716
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
Study: NCT01860716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00230971
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
Study: NCT02098395
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
Study: NCT01204918
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02382809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash, twice daily
Study: NCT02895191
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the placebo for 7 to 14 days
Study: NCT01861002
Drug: Intrathecal Methotrexate (IT MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Intrathecally to patients with ALL on day 1 of course 1 and 2.~* Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. - 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~2. - 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~3. - 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~   * 9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg
Study: NCT02709798
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02709798
Drug: 5% Glucose Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02209688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01754285
Drug: LF-PB and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01754285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00915603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO daily continuously for all 28 days of a cycle
Study: NCT03188783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
Study: NCT00226798
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03290391
Drug: Pharmacotherapy for opioid use disorder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
Study: NCT01136564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules daily
Study: NCT03134911
Drug: DOAC or VKA
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months - 2 years
Study: NCT04388176
Drug: C21
Normalized name: C18-C21 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 as first treatment
Study: NCT04388176
Drug: C21
Normalized name: C18-C21 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 as second treatment
Study: NCT04388176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as second treatment
Study: NCT04388176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as first treatment
Study: NCT02648464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02799277
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effect of testosterone on moral decision making
Study: NCT01290575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, Oral, 0.0mg, twice daily, 14 day
Study: NCT01290575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 0.0mg, once daily, 14 day
Study: NCT04633772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9%
Study: NCT02454751
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One time dose of 50mcg of fentanyl administered intranasally
Study: NCT04956939
Drug: Low dose levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Low frequency is defined as ≤ 3 LD doses a day
Study: NCT04956939
Drug: High dose levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High frequency dosage is defined as ≥ 5 LD doses per day
Study: NCT02461056
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
Study: NCT04135313
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2, bid, per os, days 1-14
Study: NCT04135313
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study: NCT00534417
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight \< 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
Study: NCT03538691
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.
Study: NCT00765817
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, twice a day
Study: NCT00263471
Drug: 7-methylxanthine
Normalized name: METHYLXANTHINES
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253888
Drug: TPV - Room condition
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253888
Drug: TPV - Refrigerated conditions
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02185456
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral metronidazole 500 mg twice a day for 7 days
Study: NCT03964688
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo intravenous during hospitalization, after oral, total 6 weeks
Study: NCT04823390
Drug: Midazolam-Fentanyl combination
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation is given to patients undergoing cataract surgery under local anesthesia
Study: NCT00092963
Drug: Comparator: placebo / Duration of Treatment: 1 day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03955809
Drug: % 0.9 NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular %0.9 NaCl
Study: NCT02475772
Drug: Cisplatin and doxorubicin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
Study: NCT02512172
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02442206
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
Study: NCT02442206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
Study: NCT02421588
Drug: Pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03827798
Drug: LOU064 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o.
Study: NCT03827798
Drug: Placebo to LOU064
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o.
Study: NCT03827798
Drug: VAY736
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c.
Study: NCT03827798
Drug: Placebo to VAY736
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c.
Study: NCT00437476
Drug: Nucleoside Reverse Transcriptase Inhibitors
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTIs for 26 weeks (A) or 24 weeks (B)
Study: NCT04304508
Drug: BAY2433334
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, taken orally once a day.
Study: NCT04733625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo medication
Study: NCT02349139
Drug: ASN001: Escalating dose Part A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen inhibitor
Study: NCT02579382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally once a week (every 7 days) for 12 doses
Study: NCT00151476
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg total daily dosing
Study: NCT03091426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT01137656
Drug: Acetylcholine and Blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
Study: NCT02706769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication contains blinded placebo
Study: NCT04027179
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
Study: NCT02797145
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
Study: NCT04099238
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
Study: NCT04098796
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
Study: NCT02634801
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT03692715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
Study: NCT00134966
Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02588586
Drug: 3BNC117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3BNC117 infusions
Study: NCT00215644
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
Study: NCT01352273
Drug: MEK162 + RAF265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02793947
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
Study: NCT01393522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down